PharmEste is a private biopharmaceutical company based on a unique Transient Receptor Potential (TRPs) ion channel technology platform that brings together strong expertise on TRPs area and industrial competences in research & development process applied to small molecule therapeutics.
The Company mission is to play a leading role in the discovery and development of fully proprietary high affinity and selective TRP channel therapeutics for the treatment of neuropathic pain, overactive bladder and other TRP-mediated diseases.
PharmEste is developing PHE377, a selective TRPV1 antagonist for the treatment of neuropathic pain. PHE377 has successfully completed the preclinical phase showing a high safety profile. Phase I clinical development is ongoing and PoC studies (Phase IIa) in patients are planned in two major clinical indications such as painful diabetic neuropathy and post herpetic neuralgia.
A second generation of TRPV1 antagonist, belonging to a chemical class different from PHE377, has been selected and a discovery program on TRPA1antagonists is ongoing in order to identify new drug candidates for the treatment of other TRP-mediated diseases. PharmEste is located both in Ferrara and Milan (Italy), it is managed by an industrial and multidisciplinary team with many years of experience and account of 12 people. The Company is supported by an outstanding international advisory board with scientific, clinical and industrial competences.
PharmEste was founded as a spin-off of the University of Ferrara and raised two round financing from International Venture Capitals.